Navigation path

Targeted Nano-Pharmaceuticals and Early Diagnostics cluster

The 'Targeted Nano-Pharmaceuticals and Early Diagnostics' cluster brings together about 25 research projects funded by the EU Sixth and Seventh Framework Programmes for Research (FP6 and FP7), under the priorities NMP and HEALTH. The projects are developing innovative therapies, detection and diagnosis methods in the field of nanomedicine and cover a wide variety of diseases including cancer, rheumatoid arthritis and osteo-arthritis, diabetes, Alzheimer's and Parkinson's disease. An important element common to each of them is an emphasis on the application of state-of-the-art nanotechnology.

The projects are each of substantial size, with a typical EU funding budget between 4 and 10 million euro. Each of them brings together specialists from 5 to 30 partner laboratories in different universities, research organisations, clinics, industries and SMEs from across Europe to collaborate on the common aim. Each of the projects has a duration of three to five years. While some have recently ended, others are just at the beginning, meaning that the composition of the cluster evolves over time.


Why a cluster of projects?

Targeted nano-pharmaceuticals

Early diagnostics

Links to other research initiatives